EPCAM and breast carcinoma: Additionally, in a case series of 100 early stage breast cancer, it was found that patients with EpCAM-enriched CTCs overexpressing TWIST1 and showing a stem cell profile, defined as CD44high/CD24−/low and ALDH1high/CD24−/low, had significantly reduced disease-free and overall survival [163].